Crescent Biopharma, Inc. (CBIO)
NASDAQ: CBIO · Real-Time Price · USD
16.84
+0.41 (2.50%)
Aug 7, 2026, 4:00 PM EDT - Market closed

Crescent Biopharma Stock Forecast

Stock Price Forecast

According to 8 analysts polled by S&P Global, Crescent Biopharma stock has a consensus rating of "Strong Buy" and an average price target of $30.6. The average 1-year stock price forecast is 81.71% higher than the current stock price, while the lowest is $27 (+60.33%) and the highest is $35 (+107.84%).

Price Target: $30.6 (+81.71%)
Analyst Consensus: Strong Buy

Price Target

Chart
TargetLowAverageMedianHigh
Price$27$30.6$28$35
Change+60.33%+81.71%+66.27%+107.84%

Analyst Ratings

The average analyst rating for Crescent Biopharma stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.

Recommendation Trends

Chart
RatingFeb '26Mar '26Apr '26May '26Jun '26Jul '26
Strong Buy888866
Buy111111
Hold000011
Sell000000
Strong Sell000000
Total999988

Latest Forecasts

AnalystFirmRatingRatingActionPrice TargetUpsideDate
Unknown Analyst
Wedbush
No rating
Wedbush
Buy
Maintains
$27
BuyMaintains$27+60.33%Jul 31, 2026
H.C. Wainwright
H.C. Wainwright
Hold
Reiterates
n/a
HoldReiteratesn/an/aJul 31, 2026
Stifel Nicolaus
Stifel Nicolaus
Buy
Maintains
$30$28
BuyMaintains$30$28+66.27%Jul 31, 2026
LifeSci Capital
LifeSci Capital
Buy
Maintains
$28
BuyMaintains$28+66.27%Jul 30, 2026
Piper Sandler
Piper Sandler
Buy
Maintains
$35
BuyMaintains$35+107.84%Jun 23, 2026
More Analyst Ratings

Financial Forecast

Revenue This Year
1.73M
from 10.84M
Decreased by -84.09%
Revenue Next Year
5.58M
from 1.73M
Increased by 223.59%
EPS This Year
-2.35
from -12.81
EPS Next Year
-2.63
from -2.35
Fiscal YearFY 2024FY 2025FY 2026
Period EndingDec 31, 2024Dec 31, 2025Dec 31, 2026
Revenue
-10.84M1.73M
Revenue Growth
---84.09%
Operating Income
-68.76M-152.63M-112.75M
Net Income
-71.47M-153.94M-105.65M
EPS
--12.81-2.35
Free Cash Flow
--153.70M-93.00M
No. Analysts
--7
EPS and Forward PE are based on non-GAAP adjusted numbers.

Revenue Forecast

Revenue202620272028
High6.0M
Avg1.7M
Low1,000,000

Revenue Growth

Revenue Growth202620272028
High
-44.7%
Avg
-84.1%
Low
-90.8%

EPS Forecast

EPS202620272028
High-2.35
Avg-2.35
Low-2.36

EPS Growth

EPS Growth202620272028
High-
Avg-
Low-